Kristin Kantautas

Rare disease drug development has a math problem. One drug. One disease. $1B+. 10+ years. That math doesn't work for 1500+ rare metabolic diseases. The proof: 80% still have no treatment. At @PerlaraPBC & Cure SRD5A3 I’ve spent 6 years discovering and developing medicines for rare diseases. The TradBio model doesn't work for rare. My takeaway: many rare metabolic diseases break down at the same hubs in metabolism. Target the hub. Treat many diseases with a single medicine. Today I'm announcing @Metabolisbio. A biotech built with my co-founder @eperlste to develop keystone medicines: a new class of treatments for rare metabolic diseases. We discover naturally occurring metabolites and develop them into medicines that can treat many rare diseases. We also run AI-powered at-home patient studies. Faster data. Lower cost. No traveling to a trial site. Our first program is NMN for DHDDS-CDG. A pediatric neurodegenerative disease. NMN has already shown it can slow disease progression in patients. Read the preprint: medrxiv.org/content/10.64898… We're raising a pre-seed round. If you believe rare disease is the proving ground for the next generation of metabolic medicines let's talk. metabolis.co

We're raising a pre-seed round. If you believe rare disease is the proving ground for the next generation of metabolic medicines, let's talk. metabolis.co

Our first program is NMN for DHDDS-CDG. A pediatric neurodegenerative disease. NMN has already shown it can slow disease progression in patients. Read the preprint: medrxiv.org/content/10.64898…

We also run AI-powered at-home patient studies. Faster data. Lower cost. No traveling to a trial site.

We discover naturally occurring metabolites and develop them into medicines that can treat many rare diseases.

Today I'm announcing @Metabolisbio. Abiotech built with my co-founder @eperlste to develop keystone medicines: a new class of treatments for rare metabolic diseases.